US23257D1037 - Common Stock - After market: 8.82 0 (0%)
NASDAQ:CBAY (3/28/2023, 7:14:51 PM)+0.09 (+1.03%)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. The company is headquartered in Newark California, California. The company went IPO on 2014-01-16. The firm is focused on developing and providing access to therapies for patients with liver and other chronic diseases. The firm's lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation, and fibrosis. The company is focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation. Its other product candidate, MBX-2982, targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion.
CYMABAY THERAPEUTICS INC
Suite 130, 7999 Gateway Blvd
Newark California CALIFORNIA 94560
P: 15102938800.0
CEO: Sujal Shah
Employees: 59
Website: https://www.cymabay.com/
CymaBay Therapeutics press release (CBAY): Q4 GAAP EPS of -$0.30 misses by $0.01.Held $135.5 million in cash, cash equivalents and investments as of December 31, 2022.
Conference call and webcast today at 4:30 p.m. ET...
NEWARK, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on...
NEWARK, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on...
NEWARK, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on...
CymaBay Therapeutics (CYMA) on Monday announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants.
Here you can normally see the latest stock twits on CBAY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: